What Yuria-pharm does

Yuria-pharm (ЮРіЯ-ФАРМ) is a privately held Ukrainian pharmaceutical group founded in 1998 that manufactures and distributes a broad portfolio of drugs and medical devices. The company operates 41 production lines across 25,000 m2 in Ukraine and 7 lines across 3,000 m2 at Diaco in Italy, with combined annual capacity exceeding 290 million units (204 million medicines and 86 million medical devices). Its 600+ registered products span infusion solutions (Reosorbilakt, Tivortin, Karnivit, Latren, Sorbilakt), antibiotics and antiseptics (Leflocin, Dekasan, Gynodek), cardiovascular and neurology products (Xavron/edavarone, Biblok, Neurocitin), respiratory therapies (Ulaizer Home nebuliser, Budesonide/Formoterol Easyhaler), medical devices (Revul hemostatic bandages, U-PORT implanted ports, Artro-Patch hyaluronic acid joint treatments, Dialiatek PD peritoneal dialysis), and functional waters (Izota, ReO, Laqua, Empati). Since 2015, the YP Biotech subsidiary has been building full-cycle biotechnological R&D infrastructure, including mRNA vaccine development, and 20+ new drugs are registered each year.

The company monetises primarily through one-time sales of pharmaceutical products and medical devices to hospitals, pharmacies, and government buyers, supplemented by hardware sales of devices and distributor/transaction-fee flows through its wholly-owned Medical Center M.T.K. distribution arm and 33,000 m2 of warehouse capacity. It is the #3 hospital distributor in Ukraine with 7.8% hospital market share, 13.4% share in parenteral products, and 3.3% of the overall Ukrainian pharmaceutical market. Exports to 41+ countries account for 25% of revenue, with recent geographic expansion into Central Asia via the 2024 acquisition of Reka-Med. Customers include Ukrainian hospitals and clinics, the Armed Forces of Ukraine and National Guard of Ukraine (notably for hemostatic products), and international distribution partners; the firm reinvests 90% of profits and targets +20% growth annually.

Name

Yuria-pharm

Legal name

ЮРіЯ-ФАРМ

Website

https://uf.ua

Company type

Private

Founded year

1998

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Yuria-pharm (ЮРіЯ-ФАРМ) is a privately held Ukrainian pharmaceutical group manufacturing infusion solutions, specialty drugs, and medical devices across 600+ registrations, serving hospitals, pharmacies, military buyers, and 41+ export markets via its own distribution network.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

Keywords

• Pharmaceutical manufacturing
• Infusion solutions
• Medical devices
• Biopharmaceutical R&D
• Hospital drug distribution

Headquarters

HQ city

Svyatoslav

HQ country

Ukraine

HQ region

Europe

Offices5 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Products: Sale of registered pharmaceutical drugs including infusion solutions, cardiovascular drugs, antibiotics, analgesics, and specialty medications through hospital and retail channels
2. Medical Devices: Sale of medical devices including inhalation systems (Ulaizer, Breather), hemostatic bandages (Revul), surgical supplies, and diagnostic equipment
3. Hospital Distribution Services: Distribution of pharmaceutical products through own distribution network (Medical Center M.T.K.) serving healthcare facilities across Ukraine
4. International Export: Export of pharmaceutical products to 41+ countries worldwide, including Central Asia, with 25% of company revenue coming from exports

Go-to-market motion1 record

Distribution channels4 records

Marketing channels8 records

Core offering

Yuria-pharm manufactures and distributes a comprehensive portfolio of over 600 registered pharmaceutical products, including infusion solutions, antibiotics, cardiovascular drugs, antiseptics, and respiratory medications, along with medical devices such as hemostatic bandages, nebulizers, and implanted port systems. The company operates its own hospital distribution network (Medical Center M.T.K.) and produces 290+ million units annually across 41 production lines in Ukraine and 7 in Italy, exporting to 41+ countries. Yuria-pharm also conducts biotech R&D through YP Biotech, including mRNA vaccine development and hyaluronic acid-based therapeutic products.

Product overview

ЮРіЯ-ФАРМ is a Ukrainian pharmaceutical group with one of the most comprehensive portfolios in the country, holding 600+ registration certificates and producing over 290 million units annually. The product portfolio is organized as a multi-category platform consisting of: (1) Infusion Solutions including Реосорбілакт®, Тівортін®, Карнівіт®, Тіворель®, Латрен®, Гекодез®, Сорбілакт®, Ксилат® for detoxification, cardiovascular, metabolic, and critical care applications; (2) Antibiotics and Antimicrobials including Лефлоцин®, Цефтриаксон, Декасан®, Гінодек®; (3) Respiratory Products including Юлайзер™ Home nebulizer system, Будесонід Ізіхейлер®, Формотерол Ізіхейлер®, Небуфлюзон®; (4) Cardiovascular and Neurology including Ксаврон (edaravone for stroke), Біблок®, Нейроцитин®; (5) Medical Devices including Ревул® hemostatic products, Емаплаг, Ю-ПОРТ implanted port systems, Діавітек peritoneal dialysis; (6) Functional Waters including Ізотa (heartburn relief), ReO (rehydration), Laqua® (medication water), Емпаті (mental health); (7) Antiseptics including Декасан®, Горостен®, Юсепт; (8) Medical Supplies including Ю-ФІКС plasters, surgical gloves, infusion sets. Manufacturing spans Ukraine (41 production lines, 25,000 m²) and Italy (Diaco - 7 lines, 3,000 m²).

Differentiator

Problem solved

Functional benefit

Brands

• YP Biotech: Biotechnology R&D division developing full-cycle biotechnological products including mRNA vaccines and biopharmaceutical active pharmaceutical ingredients
• BioGENext
• YP Biotech

Products and services

• Reosorbilakt (Реосорбілакт®)

Quantifiable outcome

• Market leader position: #3 hospital distributor in Ukraine with 7.8% hospital market share
• +4 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Five partnerships are on record, tiered core, flagship and minor.

• Reka-MedcoreStrategic or Co-development Partner · 1 January 2024Reka-Med has been welcomed into the Yuria-pharm group of companies to continue scaling operations in Central Asian countries. Reka-Med serves as a manufacturing site that will ensure supply of Yuria-pharm products in Central Asian markets and Ukraine. The company will implement Yuria-pharm quality systems and standards, positioning it as a quality benchmark for parenteral medicinal products.
• BioGENext Platform ParticipantsflagshipStrategic or Co-development Partner · 1 January 2024BioGENext is the first platform in Ukraine for interaction between scientists in biomedical sciences. Launched by Yuria-pharm R&D team, it creates a living space for exchange of experience, knowledge, and innovative ideas in biomedicine and biopharmaceutical development. The platform aims to foster quality innovative development through quality partnerships.
• State Institution Institute of Blood Pathology and Transfusion Medicine of the National Academy of Medical Sciences of UkrainecoreStrategic or Co-development PartnerResearch and development partnership for blood pathology and transfusion medicine; joint mailing list partner for healthcare professional communications
• PE InfuziaminorStrategic or Co-development PartnerPartner for healthcare professional communications and mailing list services
• Diaco (Italy)coreOEM/ Whitelabel/ Licensing PartnerItalian manufacturing partner with 7 production lines, 3,000 m2 facility, producing 33 million units annually. Part of Yuria-pharm's international manufacturing network complementing Ukrainian production capabilities.

Scale indicators14 records

Recent moves9 records

Expansion highlights6 records

Direct peers

• Farmak: Farmak is the largest pharmaceutical manufacturer in Ukraine, producing a broad portfolio of generic and branded drugs. Directly comparable as a domestic Ukrainian pharma manufacturer competing for the same hospital and retail channels across the same therapeutic areas.
• Darnitsa: Darnitsa is a top-tier Ukrainian pharmaceutical manufacturer with a broad portfolio of finished dosage forms. Comparable in scale, therapeutic breadth, and primary market overlap with Yuria-pharm in Ukrainian hospital and retail distribution.
• Arterium: Arterium is a Ukrainian pharmaceutical corporation combining manufacturing and distribution, producing branded and generic drugs. Comparable vertically integrated model and similar product categories targeting Ukrainian and CIS hospital segments.

Broad incumbents

• KRKA: KRKA is a leading Slovenian generic pharmaceutical manufacturer with broad therapeutic coverage and strong presence across Central/Eastern Europe and CIS markets. Comparable as a regional pharmaceutical manufacturer with similar hospital-channel focus and geographic expansion profile.
• Stada Arzneimittel: Stada is a major European specialty and generics pharmaceutical company with operations across multiple European markets. Comparable broad therapeutic portfolio, focus on hospital injectables and infusion solutions, and similar international distribution footprint.
• Polpharma: Polpharma is one of the largest pharmaceutical manufacturers in Central and Eastern Europe, producing APIs and finished dosage forms. Comparable regional manufacturing scale and presence across CEE/CIS markets with similar hospital-channel focus.
• Teva Pharmaceutical: Teva is the world's largest generic pharmaceutical manufacturer with a broad hospital injectables portfolio. Comparable in the infusion solutions and injectable generics therapeutic areas, though at vastly larger scale, representing a competitive incumbent in export markets.
• Gedeon Richter: Gedeon Richter is a Hungarian-headquartered pharmaceutical company with branded generic and specialty pharma operations across CEE/CIS regions. Comparable therapeutic breadth, regional footprint, and hospital/retail dual-channel model in Eastern European markets.

Emerging players

• Alvotech: Alvotech is a biopharmaceutical company specializing in biosimilars and biologic manufacturing. Comparable as an emerging biotech-focused manufacturer investing in biopharmaceutical production capabilities, though focused on biosimilars rather than Yuria-pharm's broader small-molecule portfolio.

Regional players

• Sopharma: Sopharma is a Bulgarian pharmaceutical manufacturer with strong presence in Bulgaria, CIS, and other Eastern European markets. Comparable as a regional pharma manufacturer with similar generic/specialty portfolio and export-driven growth model.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/c/YuriaPharm
• Xx.com/yuriapharm
• Facebookfacebook.com/YuriaPharm

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries4 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Yuria-pharm